Response to letter re: Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.
作者信息
Blay J-Y, Brahmi M, Dufresne A, Heudel P
机构信息
Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Equipe 4, Lyon, France.
Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Equipe 4, Lyon, France.
出版信息
ESMO Open. 2025 Apr;10(4):104531. doi: 10.1016/j.esmoop.2025.104531. Epub 2025 Mar 18.
Abstract
摘要
相似文献
1
Response to letter re: Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.对关于“抗白细胞介素-6受体抗体托珠单抗治疗实体癌副肿瘤性炎症综合征”信件的回复
ESMO Open. 2025 Apr;10(4):104531. doi: 10.1016/j.esmoop.2025.104531. Epub 2025 Mar 18.
2
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.抗白细胞介素-6受体抗体托珠单抗治疗实体癌副肿瘤性炎症综合征。
ESMO Open. 2025 Jan;10(1):104088. doi: 10.1016/j.esmoop.2024.104088. Epub 2025 Jan 3.
3
Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor.托珠单抗对与白细胞介素-6受体表达水平相对应的结直肠癌细胞异种移植瘤具有抗肿瘤作用。
Pharmaceuticals (Basel). 2024 Jan 18;17(1):127. doi: 10.3390/ph17010127.
4
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.白介素-6 与其可溶性受体的结合与类风湿关节炎患者对托珠单抗的反应相关。
Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: 10.1016/j.semarthrit.2017.10.022. Epub 2017 Nov 20.
5
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.类风湿关节炎和Castleman病患者使用抗白细胞介素-6（IL-6）受体抗体托珠单抗后血清白细胞介素-6（IL-6）和可溶性IL-6受体升高的机制及病理意义
Blood. 2008 Nov 15;112(10):3959-64. doi: 10.1182/blood-2008-05-155846. Epub 2008 Sep 10.
6
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.人源化抗IL-6R抗体托珠单抗对IL-6信号天然抑制剂可溶性gp130活性的影响。
Rheumatol Int. 2009 Feb;29(4):397-401. doi: 10.1007/s00296-008-0703-8. Epub 2008 Sep 20.
7
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.托珠单抗可抑制由mIL-6R和sIL-6R介导的信号转导，但不能抑制IL-6细胞因子家族其他成员的受体介导的信号转导。
Int Immunopharmacol. 2005 Nov;5(12):1731-40. doi: 10.1016/j.intimp.2005.05.010.
8
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.使用白细胞介素 6 受体抑制剂进行选择性免疫抑制治疗免疫相关不良事件。
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-006814.
9
COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab.COVID-19 急性呼吸窘迫综合征：托珠单抗联合西妥昔单抗联合治疗效果的模拟研究。
Br J Clin Pharmacol. 2022 Mar;88(3):1043-1053. doi: 10.1111/bcp.15009. Epub 2021 Sep 14.
10
Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential.托珠单抗治疗人类癌症的评估：最新证据与临床潜力
J Clin Pharm Ther. 2022 Dec;47(12):2360-2368. doi: 10.1111/jcpt.13781. Epub 2022 Oct 21.
本文引用的文献
1
Tocilizumab treatment for inflammatory dedifferentiated liposarcoma: pre- and post-treatment imaging and pathological changes.托珠单抗治疗炎性去分化脂肪肉瘤：治疗前后的影像学和病理变化
ESMO Open. 2025 Apr;10(4):104530. doi: 10.1016/j.esmoop.2025.104530. Epub 2025 Mar 25.
2
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.抗白细胞介素-6受体抗体托珠单抗治疗实体癌副肿瘤性炎症综合征。
ESMO Open. 2025 Jan;10(1):104088. doi: 10.1016/j.esmoop.2024.104088. Epub 2025 Jan 3.
3
A metabolic crosstalk between liposarcoma and muscle sustains tumor growth.脂肪肉瘤与肌肉之间的代谢串扰维持肿瘤生长。
Nat Commun. 2024 Sep 12;15(1):7940. doi: 10.1038/s41467-024-51827-3.
4
The biology and medical implications of interleukin-6.白细胞介素-6 的生物学和医学意义。
Cancer Immunol Res. 2014 Apr;2(4):288-94. doi: 10.1158/2326-6066.CIR-14-0022.
5
Therapeutic targeting of the interleukin-6 receptor.白细胞介素-6 受体的治疗靶向。
Annu Rev Pharmacol Toxicol. 2012;52:199-219. doi: 10.1146/annurev-pharmtox-010611-134715. Epub 2011 Sep 9.
6
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.白细胞介素-6在与肾细胞癌相关的副肿瘤性炎症综合征中的作用。
Int J Cancer. 1997 Jul 29;72(3):424-30. doi: 10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r.
7
8
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.血清白细胞介素6水平作为转移性肾细胞癌的预后因素
Cancer Res. 1992 Jun 15;52(12):3317-22.
Zotero 插件